10-04 :: April 2010
nanotimes
Companies
Facts
certified (UL 1703). The UL Master Certificate is an important validation of product quality and bankabi- lity and will be a key factor for sales of products by Oerlikon Solar customers in the fast-growing market in North America.
Oerlikon Solar has announced an additional TÜV certification for an improved module design, which will provide a stabilized efficiency of 130 Watt-peak (Wp) by the end of 2010.
http://www.oerlikon.com/solar
P
lanar Energy announced, that researchers at the University of Central Florida’s (UCF) Advanced
Materials Processing and Analysis Center (AMPAC)) have verified findings by Planar Energy that could lead to dramatic cost and performance improve- ments in large format batteries required for practical electric vehicles. “AMPAC scientists independently confirmed that Planar Energy’s new generation of
solid state electrolytes have ionic conductivity metrics comparable to liquid electrolytes used in
traditional chemical batteries,” said Dr. M.J. Soile- au, a UCF professor of optics, electrical & computer engineering and physics, who is the university’s vice president for research & commercialization. “This fundamental materials breakthrough, coupled with our proprietary low-cost manufacturing process, will render traditional chemical batteries obsolete,” de- clared Scott Faris, president and CEO of Planar Ener- gy. It will allow solid state battery fabrication that will enable manufacturers to increase their capacity by 200 to 300%, while reducing costs more than 50%.
http://www.planarenergy.com
p
Sivida Corp. (NASDAQ:PSDV) (ASX:PVA) said that a recently-published peer reviewed scien-
tific paper showed that a sustained release Durasert drug delivery device releasing the steroid fluocino- lone acetonide (FA) in the back of the eye preserved retinal function in a retinitis pigmentosa model.
“This is very encouraging,” said Dr. Ashton, CEO of pSivida Corp, “and we intend to pursue further studies using our technologies for the treatment of eye diseases for which there currently are very few effective treatments.” pSivida has developed two of the only three FDA approved ophthalmic sustained release drug delivery products, Retisert® ment of posterior uveitis and Vitrasert®
33
for the treat- for the treat-
ment of Aids-related CMV retinitis, both of which are licensed to Bausch & Lomb. The company’s third product, Iluvien®
for the treatment of diabetic macu-
lar edema is licensed to Alimera Sciences which is conducting Phase III fully recruited trials and expects to submit a New Drug Application to the FDA in the second quarter of this year. If approved, Iluvien will be the first FDA approved drug for the treatment of DME.
http://www.iovs.org/cgi/content/abstract/iovs.09-4492v1
?maxtoshow=&hits=10&RESULTFORMAT=&author1=A shton&fulltext=Retinitis+pigmentosa&andorexactfulltext =and&searchid=1&FIRSTINDEX=0&sortspec=relevance &resourcetype=HWCIT
http://www.psivida.com
Qinetiq (QQ.L); Ruane Cunniff & Goldfarb, a New York fund, bought a 10% stake.
http://www.qinetiq.com
A
rtisan Partners (U.S.), had bought just over 5% of the shares of British defense technology firm
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87